A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood

AIM: Dasatinib is a small molecule tyrosine kinase inhibitor with multiple targets including kit, PDGFR, and SRC. This prospective study evaluated the efficacy and safety of dasatinib as third‐line treatment for gastrointestinal stromal tumors (GIST). METHODS: The study enrolled adult patients (≥18 ...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Ye, Zhang, Xinhua, Wu, Xiaojun, Zhou, Yongjian, Zhang, Bo, Liu, Xiufeng, Wu, Xin, Li, Yan, Shen, Lin, Li, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476816/
https://www.ncbi.nlm.nih.gov/pubmed/32677196
http://dx.doi.org/10.1002/cam4.3319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476816/
https://www.ncbi.nlm.nih.gov/pubmed/32677196
http://dx.doi.org/10.1002/cam4.3319

Ejemplares similares